Google Translate Disclaimer

A number of pages on the Government of Saskatchewan's website have been professionally translated in French. These translations are identified by a yellow box in the right or left rail that resembles the link below. The home page for French-language content on this site can be found at:

Renseignements en Français

Where an official translation is not available, Google™ Translate can be used. Google™ Translate is a free online language translation service that can translate text and web pages into different languages. Translations are made available to increase access to Government of Saskatchewan content for populations whose first language is not English.

Software-based translations do not approach the fluency of a native speaker or possess the skill of a professional translator. The translation should not be considered exact, and may include incorrect or offensive language. The Government of Saskatchewan does not warrant the accuracy, reliability or timeliness of any information translated by this system. Some files or items cannot be translated, including graphs, photos and other file formats such as portable document formats (PDFs).

Any person or entities that rely on information obtained from the system does so at his or her own risk. Government of Saskatchewan is not responsible for any damage or issues that may possibly result from using translated website content. If you have any questions about Google™ Translate, please visit: Google™ Translate FAQs.

Achieving the Best Value for Money

These strategies are to ensure the viability of the Drug Plan and coverage for new drugs through the Saskatchewan Formulary:

Low Cost Alternative Policy
Reimbursement is calculated on the price of the lowest cost generic drug with the same effectiveness, quality, strength, and dosage.

Standing Offer Contract (SOC) Program
The Ministry of Health tenders high volume drugs to obtain the lowest possible price. A standing offer contract requires the manufacturer to guarantee delivery of specific drugs to pharmacies through approved distributors at the contracted price. In return, the manufacturer's product is used almost exclusively.

Generic Drug Pricing Strategy
Participating provinces and territories combined purchasing power and established a price point for six of the most common generic drugs at 18 per cent of the equivalent brand name drug. These six generic drugs represent approximately 20 per cent of the publicly-funded spending on generic drugs in Canada. Previously individual provinces and territories pay between 25 and 40 per cent of brand name prices.

Maximum allowable cost (MAC) policy
The policy promotes the use of lower cost drugs. The Drug Plan uses the prices of the most cost-effective drugs as benchmarks. Based on these benchmarks, the Drug Plan sets the maximum reimbursable prices of other similar drugs that treat same conditions.

Product Listing Agreements (PLAs)
These agreements result in better value and assist in managing the financial risk associated with drugs listed on the Saskatchewan Formulary. More information on PLAs.

We need your feedback to improve Help us improve